Taken together, the DNAJB1-PRKACA fusion transcript-based peptide vaccine Fusion-VAC-XS15 combined with the immune checkpoint inhibitor atezolizumab is an innovative and promising combinatorial immunotherapeutic treatment option for the devastating tumor disease FL-HCC and other cancer entities carrying the DNAJB1-PRKACA fusion transcript. The gene discussed is PRKACA; the disease is hepatocellular carcinoma.